A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

Launched by MERCK SHARP & DOHME LLC · Apr 7, 2025

Keywords

ClinConnect Summary

This clinical trial, called the LIGHTRAY EXTENSION, is studying a medicine called sotatercept (MK-7962) for people with pulmonary arterial hypertension (PAH), a condition that affects blood flow in the lungs. The goal of this study is to learn more about how safe sotatercept is when given in doses based on a person's weight range, rather than their exact weight. This trial is for individuals who previously participated in a related study and completed their treatment successfully.

To be eligible, participants must have finished the earlier study without stopping the treatment and should not have started taking commercially available sotatercept or other specific treatments. If you join this study, you can expect to receive sotatercept in a weight-banded dose and be monitored for safety and how well you tolerate the medication over a longer time. This is an important step in finding new treatment options for PAH, and it offers a chance to contribute to research that could help many people.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The main inclusion criteria include but are not limited to the following:
• • Has completed the treatment period of study MK-7962-024 (LIGHTRAY) (including Visit 11) on study intervention, did not discontinue study intervention, and is able to safely enroll into MK-7962-031 (LIGHTRAY EXTENSION)
• • Has not started treatment with commercially available sotatercept
• Exclusion Criteria:
• The main exclusion criteria include but are not limited to the following:
• • - Has current exposure or is planning to begin treatment with an activin signaling inhibitor (other than sotatercept)